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Introduction {#sec1}
============

We previously determined that, by both gene expression and functional analyses, the derivatives of human pluripotent stem cells (hPSCs) more closely resembled cell types found prior to 6 weeks of gestation than later time points ([@bib31]). In fact, this appears to be an emerging theme in hPSC differentiation ([@bib5; @bib24; @bib44]). This suggests that hPSC derivatives are developmentally immature, which could stem from either inadequate culturing methods or could suggest that developmental timing is somewhat conserved in vitro.

Among the most differentially expressed genes in all PSC derivatives are *LIN28A* and *LIN28B*, RNA binding proteins known to regulate the *let-7* family of miRNAs ([@bib31]). *LIN28B* seems to function primarily in the nucleus by sequestering *pri-let-7*s to prevent maturation by Microprocessor, whereas *LIN28A* functions in the cytoplasm by recruiting uridylyl transferase to polyuridylate the pre-*let-7*s and prevent their further processing by Dicer ([@bib11; @bib12; @bib20; @bib21; @bib33]). In lower organisms, *Lin28A* expression is strongly correlated with the differentiation status and self-renewing capacity of cells throughout development. Although there is less evidence for the role of this pathway in human development specifically, many groups have demonstrated that *LIN28A* is reexpressed in a variety of human cancers and is highly correlated with prognosis and disease progression ([@bib36; @bib40]). Furthermore, *LIN28A* has also been used to reprogram somatic cells back to the pluripotent state ([@bib41]). All of these known roles are linked to developmental progression and make *LIN28A/B-let-7* an attractive candidate for manipulating the maturity of hPSC-derived cells.

Previous work by other groups in lower organisms has argued that *Lin28A* plays a role in maturation of the nervous system ([@bib2]), and some have shown that overexpression of *LIN28B* in human adult hematopoietic stem/progenitor cells can reverse their developmental progression to a fetal-like state ([@bib43]). Downstream of LIN28A/B, however, a role for *let-7* in human gestational maturation in the nervous system has not been established. In fact, one study of a murine model has suggested that the role of *Lin28A* in developmental progression was *let-7* independent ([@bib2]). Recent work has also suggested that LIN28/*let-7* regulates neurogenesis by controlling the proliferation of progenitors ([@bib7; @bib28]). Here, we explore the role of the *LIN28*/*let-7* pathway in the developmental progression of human neural progenitor cells (NPCs). We demonstrate that *LIN28B* plays a clear role in gestational progression of the developing human nervous system through regulation of *let-7* miRNAs. These miRNAs then go on to regulate *HMGA2*, which has also been implicated in developmental progression ([@bib34]). We also show here that *HMGA2* appears to regulate cell-fate decisions in neural progenitors (NPCs) in this context through *HES5*, a key node in the NOTCH pathway and previously implicated in neurogenesis.

Results {#sec2}
=======

PSC-NPCs Are Functionally and Transcriptionally Distinct from Tissue-Derived Counterparts {#sec2.1}
-----------------------------------------------------------------------------------------

During mammalian development, NPCs progress through several phases: an early expansion phase, characterized by symmetric divisions; a neurogenic phase, characterized by asymmetric divisions and resulting in new neurons; a gliogenic phase where astrocytes are primarily produced; and finally a phase where oligodendrocytes are generated ([Figure 1](#fig1){ref-type="fig"}). The result is that neurogenesis precedes gliogenesis on a developmental timescale.

NPCs were derived from either hPSCs or from fetal tissue sources and were validated by immunostaining and judged to be relatively homogenous ([Figure S1](#app2){ref-type="sec"}A; [@bib31]). We determined that PSC-NPCs across all passages had a higher propensity to differentiate into MAP2/TUJ1^+^ neurons (∼50%) over GFAP/S100/A2B5^+^ glia (\<10%) ([Figure 1](#fig1){ref-type="fig"}A). Meanwhile, tissue-derived NPCs isolated from fetal brain or spinal cord samples at 12--19 weeks of gestation (Tissue-NPCs) were more apt to differentiate into glia (∼70%) over neurons (\<20%) ([Figure 1](#fig1){ref-type="fig"}A; [@bib31]). These data suggest that PSC-NPCs were functionally less mature than tissue-derived counterparts (neurogenesis precedes gliogenesis). Furthermore, we have previously shown that upon subsequent passage of PSC-NPCs the propensity for gliogenesis increased but still did not approach that of tissue-derived cells ([@bib31]).

To understand the molecular basis for this observed functional discrepancy, gene expression profiling was performed on PSC derivatives and tissue-derived counterparts ([@bib31]). Among the most differentially expressed genes were *LIN28A* and *LIN28B* ([Figures 1](#fig1){ref-type="fig"}B, top, and [S1](#app2){ref-type="sec"}C), and this was confirmed at the protein level by immunostaining ([Figure 1](#fig1){ref-type="fig"}B, bottom). Although continued passaging reduces the levels of *LIN28A* and *LIN28B* in PSC-NPCs, their expression is not decreased to a level found in the Tissue-NPCs within the time points utilized for this study ([Figure 1](#fig1){ref-type="fig"}B; [@bib31]).

*LIN28* homologs are known to negatively regulate the highly conserved *let-7* family of miRNAs. Our previous microarray analyses demonstrated a significantly higher expression of some *let-7* miRNAs in Tissue-NPCs ([Figure S1](#app2){ref-type="sec"}C), and this result was confirmed by direct sequencing of mature miRNA ([Figure 1](#fig1){ref-type="fig"}C; [Table S1](#mmc2){ref-type="supplementary-material"}). The latter analysis demonstrated that not only were all *let-7* family members significantly higher in Tissue-NPCs, as we had previously shown by RT-PCR ([@bib31]), but all nine family members were found among the top 30 differentially expressed miRNAs between Tissue-NPCs and PSC-NPCs ([Table S1](#mmc2){ref-type="supplementary-material"}). Furthermore, the *let-7* family as a whole was the most abundantly expressed miRNA family in 16 week Tissue-NPCs, representing almost 18% of the total miRNA in these cells. In addition, *let-7* family members were expressed at an intermediate level in 6--7 week Tissue-NPCs.

To determine whether *let-7* target genes were among the differentially expressed mRNA distinguishing PSC-NPCs from their tissue-derived counterparts, two lists of *let-7* targets were generated ([Figure 1](#fig1){ref-type="fig"}D): one with published *let-7* targets that have been experimentally confirmed (77 genes) and one with predicted *let-7* targets generated by TargetScan 5.2 (751 genes). Of the 77 published *let-7* targets, 20 were differentially expressed between PSC-NPCs and Tissue-NPCs, and 134 of the 751 TargetScan predicted *let-7* targets were differentially expressed. Notably, 95% and 63%, respectively, were specifically lower in Tissue-NPCs, consistent with a negative regulatory activity of *let-7* in tissue-NPCs.

Recent work in mice has suggested that during neurogenesis, the induction of *let-7* leads to exit of the cell cycle and differentiation toward neurons ([@bib7; @bib28]). Analysis of eight tissue-derived NPCs and three PSC-derived NPCs failed to find consistent differences in the percentage of cells in S or G2/M phase of the cell cycle ([Figure 1](#fig1){ref-type="fig"}E), suggesting that despite having orders of magnitude more *let-7* ([Figure 1](#fig1){ref-type="fig"}C), Tissue-NPCs can still maintain a proliferative state.

To determine when the transition from neurogenesis to gliogenesis occurs endogenously, we probed developmental transcriptome data for glial hallmark genes from the Allen Brain Atlas. GFAP, AQP4, and S100B were all expressed at a low level in all brain regions prior to 12 weeks but surged thereafter suggesting that gliogenesis begins in the human brain at roughly 12 weeks of gestation. A similar examination of oligodendrocyte markers suggests that oligodendrogenesis begins at 24 weeks ([Figure 1](#fig1){ref-type="fig"}F, middle). These gene expression data are consistent with pathological data on fetal tissue showing oligodendrocyte progenitors prevalent at 20 weeks of gestation and mature oligodendrocytes at 30 weeks ([@bib8; @bib9; @bib16]). Notably, the expression of *LIN28B* in human brain was only detectable in weeks 8--9 of gestation and dropped off significantly thereafter ([Figure 1](#fig1){ref-type="fig"}F, middle), whereas *LIN28A* was undetectable in these analyses. *let-7* miRNAs were also detectable in these data sets, and this family showed a striking induction across the human brain in the 9--12 postconception week (PCW) time frame ([Figure S1](#app2){ref-type="sec"}B). Taken together, these data suggested that there is a strong correlation between the transition from high*LIN28*/low*let-7* to low*LIN28*/high*let7* state and the switch from neuro- to gliogenesis. Therefore, we hypothesized that the *let-7* plays a functional role in the decision to make either neurons or glia by neural progenitors ([Figure 1](#fig1){ref-type="fig"}G).

*let-7* Expression and Processing across Development {#sec2.2}
----------------------------------------------------

*LIN28A/B* controls the maturation step to generate mature *let-7* ([@bib12; @bib32; @bib33; @bib37]), and *LIN28A* and *B* are also *let-7* targets. A priori, we expected that levels of *let-7* rose during development as a result of *LIN28A/B* downregulation over time. To understand the dynamics of *let-7* processing during development, we assessed the levels of pri, pre, and mature *let-7* miRNAs ([Figure 2](#fig2){ref-type="fig"}), we used RT-PCR to detect specifically mature *let-7* family members in NPCs and found that, similar to what was found by miRNA sequencing (miRNA-seq) profiling ([Figure 1](#fig1){ref-type="fig"}D), all *let-7* family members were dramatically higher in Tissue-NPCs compared to PSC-NPCs ([Figure 2](#fig2){ref-type="fig"}A; [@bib31]). Conversely, by using a miRNA RT-PCR approach that strictly measures primary *let-7* transcripts, we determined that *pri-let-7b* and *pri*-*let-7a2* transcript levels are significantly higher in Tissue-NPCs, whereas all the other tested members of the *let-7* family were essentially unchanged ([Figure 2](#fig2){ref-type="fig"}C). Similarly, a separate approach that can distinguish pri- and pre-*let-7* messages from mature *let-7* miRNAs also showed that pre-*let-7b* was the only *let-7* family member assayed that was differentially expressed in Tissue- versus PSC-NPCs ([Figure 2](#fig2){ref-type="fig"}B). Interestingly, *let-7b* and *let-7a3* are known to be expressed from the same locus ([@bib38]), whereas *let-7a1* and *let-7a2* are transcribed from different loci.

Passaging of PSC-NPCs results in a decrease of both *LIN28A* and *LIN28B* ([Figure 1](#fig1){ref-type="fig"}B; [@bib31]) and increase of mature *let-7*s ([Figure 2](#fig2){ref-type="fig"}E; [@bib31]), suggesting a functional link between *LIN28* expression and levels of mature *let-7* as expected ([@bib12; @bib13]). Interestingly, when assaying for pri-miRNA transcripts, many of the pri-*let-7*s were also induced during passaging as detected by both RT-PCR ([Figure 2](#fig2){ref-type="fig"}F) and Chromatin-RNA-seq (discussed more below; [Figure 2](#fig2){ref-type="fig"}G), which presumably occurred independently of any direct regulation by LIN28 protein, because they are not thought to play any role in regulation of transcription of pri-*let-7*s. These results point toward the existence of undescribed regulatory mechanisms governing *let-7* transcription independent of *LIN28* during human gestation.

To further verify the apparent transcriptional regulation of the *let-7* family, we employed an approach whereby chromatin-associated RNA is captured and sequenced ([@bib3]). This approach generates data on relative amounts of nascent transcript, and therefore a bona fide measure of transcription as opposed to steady-state levels of RNA. Consistent with results from RT-PCR, transcription at the *let-7a3/let-7b* locus was significantly different between PSC-NPCs and Tissue-NPCs, demonstrating a *LIN28A/B* independent regulation of *let-7* ([Figures 2](#fig2){ref-type="fig"}D and 2G). These data also suggest that the *let-7* family of miRNAs is each subject to unique modes of transcriptional regulation that occurs prior to the actions of *LIN28A/B* on *let-7* maturation. Also shown is the expression of several unrelated miRNAs (miR-10, 15A, 15B) to demonstrate that the *let-7* effect is specific to this family and not indicative of imbalanced analysis ([Figure 2](#fig2){ref-type="fig"}G). This method allowed for a complete annotation of human *let-7* transcriptional loci based on analysis of transcribed RNA, as opposed to in silico prediction, and showed a large degree of polycistronic expression of groups of *let-7* family members ([Table S2](#app2){ref-type="sec"}).

Manipulation of LIN28A/B Shows a Modest Effect on Developmental Maturity of NPCs {#sec2.3}
--------------------------------------------------------------------------------

To determine what role *LIN28* had on the developmental maturity of NPCs, we utilized two strategies. First, we used a small interfering RNA (siRNA) approach to knockdown both homologs. When si*LIN28A* and si*LIN28B* were introduced by transfection, mRNA for these genes was suppressed by 70%--75% as measured by RT-PCR ([Figure S3](#app2){ref-type="sec"}A). This was also confirmed by western blot ([Figure S3](#app2){ref-type="sec"}B). As a result of this knockdown, mature *let-7* family miRNAs accumulated, as measured by RT-PCR, relative to transfection of a nontarget (siNT) control ([Figure S3](#app2){ref-type="sec"}C). Also of note, siRNAs against both homologs were necessary to observe an induction of the *let-7* family members, demonstrating their known semiredundant roles in *let-7* maturation ([@bib26]).

Microarray profiling identified many genes differentially expressed as a result of si*LIN28A/B* dual knockdown. However, these differentially expressed genes did not significantly overlap with the original list of probe sets differentially expressed between PSC-NPCs and their tissue-derived counterparts ([Figure S3](#app2){ref-type="sec"}H; [@bib31]), nor were *let-7* downstream targets, besides *LIN28A* and *LIN28B*, selectively knocked down ([Figure S3](#app2){ref-type="sec"}F). In addition, the dual knockdown had no effect on the propensity to differentiate into neurons or glia ([Figure S3](#app2){ref-type="sec"}D). These findings suggested that RNAi based knockdowns can lower *LIN28* expression and induce *let-7* maturation, but the resulting subtle *let-7* induction exerted little effect functional effect. The second strategy to assess the functional relevance of *LIN28B* in NPC maturation utilized re-expression in Tissue-NPCs. When *LIN28B* was overexpressed in Tissue-NPCs by viral infection, mature *let-7* levels decreased ([Figure S3](#app2){ref-type="sec"}E), a portion of the differentially expressed genes between Tissue-NPCs and PSC-NPCs were corrected ([Figure S3](#app2){ref-type="sec"}H), including some *let-7* target genes ([Figure S3](#app2){ref-type="sec"}F). Importantly, neurogenesis was promoted at the expense of gliogenesis upon induction of *LIN28B* in Tissue-NPCs ([Figure S3](#app2){ref-type="sec"}G).

Direct Manipulation of *let-7* Levels Alters Cell Fate in Neural Progenitors {#sec2.4}
----------------------------------------------------------------------------

Previous studies either did not directly address the role of *let-7* in *LIN28*-mediated developmental progression or ruled it out altogether ([@bib2; @bib43]). To assay whether *let-7* miRNAs play a role in Tissue-NPCs, we introduced antagomirs against *let-7b* and *let-7g*. Microarray analysis on two independent experiments demonstrated that *HMGA2* specifically was strongly induced by antagomirs compared to nonspecific controls at both the RNA and protein levels ([Figures 3](#fig3){ref-type="fig"}A and 3B). Looking at global gene expression, 649 probe sets were differentially expressed between *let-7b/g* antagomir-treated and nontarget controls (antag CTRL). Of these probe sets, 181 overlapped with previous comparisons between PSC- and Tissue-NPCs (p = 3.72 × 10^−55^, [Figure 3](#fig3){ref-type="fig"}C), and *let-7* targets were specifically increased in these cells as expected ([Figure 3](#fig3){ref-type="fig"}D). Furthermore, Tissue-NPCs transfected with *let-7b/g* antagomirs were significantly more similar to PSC-NPCs than antag-CTRL-transfected cells on a global transcriptome level as measured by Pearson correlation ([Figure 3](#fig3){ref-type="fig"}E). Together, these data indicated that levels of *let-7* in PSC- and Tissue-NPCs play a role in the transcriptional disparity between these sources of NPCs, and that manipulation of *let-7* levels can shrink the dissimilarity between them. Finally, when antagomirs against *let-7b/g* were introduced into Tissue-NPCs, they became significantly more neurogenic and less gliogenic ([Figure 3](#fig3){ref-type="fig"}F; p \< 0.005).

To determine whether gliogenesis in PSC-NPCs could be regulated by *let-7*, mature oligonucleotides (mimics) for *let-7b* and *let-7g* were transfected into PSC-NPCs. Several *let-7* targets (*LIN28A*, *LIN28B*, *HMGA2*, *IGF2BP1*, and *PLAGL2)* were suppressed as measured by microarray profiling ([Figure 4](#fig4){ref-type="fig"}A). Global expression analysis of the of *let-7* mimic-treated NPCs over two independent experiments identified 331 probe sets differentially expressed between *let-7b/g*-transfected PSC-NPCs over respective nonspecific mimic control (miCTRL). Furthermore, among the transcriptional differences observed between these two conditions a significant number overlapped with the original list of genes differentially expressed between PSC- and Tissue-NPCs (p = 3.76 × 10^−46^, [Figure 4](#fig4){ref-type="fig"}B). Focusing on direct *let-7* downstream targets, expression profiling determined that not only were *let-7* target genes overrepresented in the data, but they were specifically downregulated in *let-7b/g*-transfected NPCs over miCTRLs ([Figure 4](#fig4){ref-type="fig"}C). Furthermore, *let-7b/g*-transfected PSC-NPCs were significantly more similar to 16--19 week tissue-NPCs than miCTRL-transfected PSC-NPCs on a transcriptome level as measured by Pearson correlation ([Figure 4](#fig4){ref-type="fig"}D). Following *let-7* induction, the PSC-NPCs were differentiated for 3 weeks in growth factor withdrawal media. miCTRL-transfected NPCs overwhelmingly produced TUJ1^+^ neurons, whereas only rare GFAP^+^ cells were found. When *let-7b/g* mimics were transfected prior to differentiation, the PSC-NPCs were slightly less neurogenic and significantly more gliogenic ([Figure 4](#fig4){ref-type="fig"}E; p = 3.58E^−05^).

Taken together, experiments that employed direct regulation of *let-7* levels showed significant effects in both PSC- and Tissue-NPCs at both the molecular and functional levels, whereas attempts to manipulate *LIN28A/B* yielded more subtle effects. This observation is summarized in [Figure S3](#app2){ref-type="sec"}, where manipulation of *LIN28A/B* only showed modest effects on both gene expression and differentiation in NPCs ([Figures S3](#app2){ref-type="sec"}G and S3H). Instead, direct manipulation of *let-7* clearly shows that this miRNA family can control the fate of NPCs ([Figures 3](#fig3){ref-type="fig"} and [4](#fig4){ref-type="fig"}), in contrast to what was shown in a murine model ([@bib2]).

*let-7* Acts through HMGA2 to Control Cell Fate {#sec2.5}
-----------------------------------------------

We hypothesized that the key *let-7* target genes responsible for cell fate in our model should show differences in gene expression levels in experimental settings presented here where NPC fate was affected ([Figures 1](#fig1){ref-type="fig"}A, [4](#fig4){ref-type="fig"}E, and [5](#fig5){ref-type="fig"}F). Taking the genes changed in every experimental model we produced that correlated with changes in neurogenesis versus gliogenesis, we narrowed the list of candidate genes. We furthered narrowed the list by taking gene expression data from the Allen Brain Atlas to identify genes changed from the pregliogenic state to the gliogenic stage (8--9 weeks PCW versus 16--18 weeks postconception) ([Figure 6](#fig6){ref-type="fig"}A). Just six genes appeared to have expression patterns that correlate with the switch from neurogenesis to gliogenesis in all these settings ([Figure 5](#fig5){ref-type="fig"}A). Of these six genes, two were predicted *let-7* target genes (*HMGA2* and *GABBR2*), but only *HMGA2* has been implicated in neurogenesis ([@bib34]). *HMGA2* was shown to affect cell fate in the murine brain ([@bib27; @bib34]) as well as various tissues ([@bib25; @bib42]) and is thought to be mostly expressed prenatally ([@bib1; @bib10]). We found that *HMGA2* was among the genes whose expression was limited to fetal brain prior to 10 weeks of gestation, just prior to the surge of gliogenesis predicted by the Allen Database ([Figure 1](#fig1){ref-type="fig"}F).

A closer look at *HMGA2* transcription shows that at least eight transcripts are produced from this locus. One of these transcripts contains a large 3′ UTR that contains six *let-7* binding sites, whereas the other transcripts are predicted to be much less sensitive to suppression by *let-7*. Reanalysis of expression analysis by array with various probe sets that each recognize distinct transcripts showed that the dominant transcript expressed contains multiple *let-7* sites (identified by 208025_s\_at), and that this is the only one affected by *let-7* manipulation (data not shown; [Figure 5](#fig5){ref-type="fig"}B). Furthermore, this particular transcript is the only one differentially expressed between PSC- and Tissue- NPCs ([Figure 5](#fig5){ref-type="fig"}B). The difference in expression of *HMGA2* between Tissue- and PSC- NPCs was also obvious at the protein level ([Figure 5](#fig5){ref-type="fig"}C). Taken together, these data suggested that suppression of *HMGA2* levels by induction of *let-7* correlated with the switch from neurogenesis to gliogenesis in the nervous system. To directly test the role of *HMGA2* in the developmental progression of PSC-NPCs, we silenced this gene by RNAi prior to terminal differentiation. Three distinct siRNAs were used (a--c), and just one of them (siHMGA2b) was predicted to target the long isoform with *let-7* sites. *HMGA2* message was suppressed by this method at both the RNA ([Figure 5](#fig5){ref-type="fig"}D, left) and protein levels ([Figure 5](#fig5){ref-type="fig"}D, right). As with induction of *let-7* mimics, suppression of *HMGA2* significantly induced gliogenesis in PSC-NPCs ([Figure 5](#fig5){ref-type="fig"}E).

The Notch Pathway Is a Key Effector of *let-7* in Gliogenesis {#sec2.6}
-------------------------------------------------------------

Profiling RNA expression after HMGA2 KD uncovered a modest number of genes changed. Intersection of these genes with those that were changed during human neurogenesis (Allen Database) or in Tissue-NPCs where *let-7* was inhibited by antagomirs found just two genes consistently altered (*HES5* and *USP44*)([Figure 6](#fig6){ref-type="fig"}A). Significantly, *HES5* is a key target gene and effector of the NOTCH pathway, and perhaps the best known regulator of gliogenesis in mice ([@bib15; @bib17; @bib18; @bib29; @bib30]). RT-PCR of PSC-NPCs with knockdown of *HMGA2* clearly showed decreased *HES5* levels, suggesting a functional correlation between the two ([Figure 6](#fig6){ref-type="fig"}B). This correlation did not appear to be due to a difference in the activity of NOTCH, as both PSC and Tissue-NPCs showed similar activity ([Figure 6](#fig6){ref-type="fig"}C). Although NOTCH signaling has been shown to either promote or inhibit gliogenesis depending on the context, in our human model abrogation of all NOTCH signaling with gamma-secretase inhibitor (DAPT) stimulated gliogenesis and suppressed neuronal differentiation ([Figure 6](#fig6){ref-type="fig"}D).

Using the Allen database, it is clear that *HES5* is coexpressed with HMGA2 at 8--11 weeks of gestation just prior onset of gliogenesis, and expression of both genes drop significantly thereafter ([Figure 6](#fig6){ref-type="fig"}E). On the other hand, most other NOTCH effectors did not significantly change over the same time ([Figure S4](#app2){ref-type="sec"}A). Expression patterns for *HES5* across nine different human cell types representing derivatives of all three germ layers suggested that *HES5* is restricted to the nervous system, whereas the other *HES/HEY* family members had a more widespread distribution throughout various organs ([Figures 6](#fig6){ref-type="fig"}F and [S4](#app2){ref-type="sec"}B). This analysis also showed that PSC-NPCs expressed the highest levels of *HES5*, followed by lower expression in Tissue-NPCs, which were more gliogenic ([Figure 1](#fig1){ref-type="fig"}A; [@bib31]).

In order to functionally probe for a link between *HES5* and *let-7*, this miRNA was experimentally abrogated in Tissue-NPCs with antagomirs while suppressing *HES5* induction with siRNA. As shown above ([Figure 3](#fig3){ref-type="fig"}F), suppression of *let-7*s with antagomirs increased neurogenesis and decreased gliogenesis in Tissue-NPCs, but when *HES5* induction was simultaneously blocked by siRNA ([Figure 6](#fig6){ref-type="fig"}G), this effect was lost ([Figure 6](#fig6){ref-type="fig"}H). This result was consistent with the described role for *HES5* in murine neural development in the absence of LIF, whereas, in the presence of LIF, *HES5* has a progliogenic role ([@bib4; @bib6; @bib14]).

As an AT-hook binding protein, *HMGA2* is well known to be broadly associated with chromatin. To begin to understand why *HMGA2* expression strongly correlated with *HES5* levels in NPCs, we probed whether *HMGA2* can regulate access of NICD/RBPj transcriptional complexes to the *HES5* promoter in response to NOTCH activation. Chromatin immunoprecipitation (ChIP) for NICD uncovered significant binding to two RBP binding sites within the *HES5* regulator region ([Figure 6](#fig6){ref-type="fig"}I), as expected in cells with strong NOTCH activation ([Figure 6](#fig6){ref-type="fig"}C). On the other hand, when *HMGA2* expression was abrogated by siRNA, NICD did not appear to significantly associate with these same sites, consistent with the notion that *HMGA2* plays a role in regulating access of NICD to the *HES5* promoter.

The *let-7* Effect on Gliogenesis Extends to Oligodendrocyte Formation {#sec2.7}
----------------------------------------------------------------------

The fact that induction of *let-7* drove PSC-NPCs toward a more astrocytic fate suggested that *let-7* could play an important role in developmental switches. In the same vein, established protocols to generate oligodendrocytes with PSC-NPCs normally take at least 17 weeks ([@bib35; @bib39]), which is akin to the time it takes to produce them in utero ([Figure 1](#fig1){ref-type="fig"}F). Using one of these protocols, we observed oligodendrocyte progenitors (OPCs) and mature oligodendrocytes after just 6--7 weeks of culture, but only in PSC-NPCs cultures following *let-7* induction at the NPC stage ([Figure 7](#fig7){ref-type="fig"}). These cells were judged to be bona fide oligodendrocytes on the basis of coexpression of O4 and Myelin Basic Protein (MBP) in confocal imaging. This result again suggested that *let-7* can play a role in the developmental maturity of PSC-NPCs and provides an approach to speed the generation of astrocytes and oligodendrocytes from human PSCs.

Discussion {#sec3}
==========

The critical advance of this study is definitively showing that *let-7* levels not only correlate with developmental progression in the human nervous system, but also serve to functionally drive the transition. Furthermore, whereas the *let-7* target gene *HMGA2* had previously been shown to promote neurogenesis in murine NPCs, we showed here that this is also the case for humans as well. Finally, we provide evidence that the mechanism by which *let-7* miRNAs drives progression in the nervous system is by altering expression of a key NOTCH effector gene *HES5*. This NOTCH effector, and NOTCH signaling in general, has been shown to be a promoter of gliogenesis in murine models, whereas our data suggest a proneurogenic role. This discrepancy could be due to several obvious differences in context: murine versus human models, the presence or absence of LIF signaling, and/or in vitro versus in vivo settings. Nevertheless, the effect in this human setting was clear: inhibiting NOTCH activity generated NPCs that went from negligible numbers to a state where over 10% of differentiated cells were astrocytes. We did not try the converse experiment, inducing NOTCH activity, because it appeared as though all NPCs tested, whether neurogenic or gliogenic, showed considerable NOTCH activity. Interestingly, data presented here suggest that no other NOTCH effectors were affected by *let-7* or *HMGA2* manipulation, only *HES5*. These data suggest that the Notch pathway can be regulated by *HES/HEY* effectors by fine-tuning access to the binding sites of its effectors.

However, this study provides only a partial understanding of the relation between HMGA2 and regulation of Notch signaling. This is due in part to a poorly defined binding pattern of HMGA2 throughout the genome. It is known to be abundant when expressed during development and, as an AT-binding protein, can in theory bind nearly the entire genome. Thus, whereas we show here that the expression of HMGA2 appears to affect access of NICD to the HES5 promoter, it is unclear whether this is due to direct binding at this locus, or a general effect on chromatin compaction.

This study also highlights a role for transcriptional control of let-7 miRNAs in development. It was thought that primary *let-7* transcription occurred at a constant level, and that levels of mature *let-7* were strictly a matter of *LIN28* activity. However, data provided here clearly demonstrate that *let-7b* is regulated at the transcriptional level even in cells that do not express *LIN28A/B*. Our data suggest that, developmentally, one *let-7* family member (pri-*let-7b*) is induced at the transcriptional level prior to the loss of *LIN28A/B* protein and may be a key driver of *LIN28A/B* suppression as gliogenesis is initiated. It will be important to determine whether the methods developed here to facilitate developmental progression also apply to cells that have been transplanted into tissue.

Experimental Procedures {#sec4}
=======================

Cell Culture {#sec4.1}
------------

Undifferentiated hPSC lines HSF1, H9, and xiPSC2 were maintained as previously described ([@bib23]) and in accordance with UCLA ESCRO. Neural progenitors were derived through formation of neural rosettes and maintained and further differentiated as described ([@bib19]). NPCs were derived from fetal tissue (either brain or spinal cord) as described. All NPCs were judged to be pure by immunostaining as described ([@bib31]) ([Figure S1](#app2){ref-type="sec"}).

Transfection {#sec4.2}
------------

siRNAs (Thermo Dharmacon), *let-7* mimics (Thermo Dharmacon), and *let-7* antagomirs (Thermo Dharmacon "inhibitors") were transfected with Lipofectamine RNAiMAX (Invitrogen) at a ratio of 5 μl lipofectamine:20 nM siRNA or 5 μl lipofectamine:40 nM mimic or antagomirs for each well of a 6-well plate. A reverse transfection method was used. Briefly, Lipofectamine and oligos were premixed in 1 ml of OptiMEM (Gibco) for 25 min in the precoated receiving plate. Cells were then passaged with TrypLE (Gibco), resuspended in 1 ml of NPC media without antibiotics, and plated on top of transfection media. Transfections were incubated overnight at 37°C after which time media was replaced with standard NPC culturing media with antibiotics for the indicated lengths of time. Lentivirus for CMV-LIN28B-SV40-mCherry (Genecopoeia) or UBC-mCherry (Kohn lab) was made by the UCLA vector core. NPCs were reverse infected overnight in NPC media without antibiotic.

Immunostaining {#sec4.3}
--------------

PSC-NPCs or Tissue-NPCs differentiated for 3 weeks were passaged with TrypLE (GIBCO) to glass coverslips 2--7 days before fixing. Coverslips were fixed and stained using standard protocols as described ([@bib31]). Primary antibodies included rabbit × TUJ1 (1:2,000; Covance), rabbit × GFAP (1:1,000; Dako), rabbit × S100 (1:1,000; Dako), chicken × GFAP (1:2,000, Abcam), mouse × MAP2 (1:500; Abcam), rabbit × Cleaved Notch1 (Val1744) (1:500; Cell Signaling Technologies), rabbit × LIN28A (1:300; Cell Signal), rabbit × LIN28B (1:300; Cell Signal), rabbit × HMGI-C (HMGA2) (1:200, Santa Cruz Biotechnology), mouse × O4 (1:300; R&D Systems), rat × MBP (1:50; Abcam), mouse × A2B5 (1:1,000; Abcam). All images were captured on a Zeiss microscope using Axiovision software (Zeiss) for image capture. GFAP or TUJ1 positive cells were counted using ImageJ software as a percentage of the total DAPI-labeled nuclei or as a percentage of the mCherry^+^ cells within the field. Average percentage positive cells and SEM was calculated over at least six fields of view. Western blot analysis was performed using standard procedures as described ([@bib22]). Primary western blot antibodies include rabbit × HMGI-C (1:500; Santa Cruz), rabbit × LIN28A (1:500; Cell Signal), rabbit × LIN28B (1:500; Cell Signal), and mouse × actin (1:1,000).

Additional materials and methods can be found in the [Supplemental Information](#app2){ref-type="sec"}.

Author Contributions {#sec5}
====================

M.P. and X.G.: conception and design, collection and assembly of data, data analysis and interpretation, manuscript writing, final approval of manuscript; K.L., M.E., J.C., Y.X., J.L., S.A., S.M.D.: collection and assembly of data; S.S. and M.P.: data analysis and interpretation; W.E.L.: conception and design, data analysis and interpretation, manuscript writing, final approval of manuscript, and financial support.

Supplemental Information {#app2}
========================

Document S1. Supplemental Experimental Procedures, Figures S1--S4, and Table S2Table S1. miRNA Sequencing on PSC- and Fetal-Derived NPCsDocument S2. Article plus Supplemental Information

We would like to thank the core facilities at UCLA (Flow Cytometry Core, EEBRCM; Clinical Genomics, Pathology). We would also like to thank Wen Gu for help with cell-cycle analysis and Gerry Weinmaster for useful suggestions on the Notch pathway. M.P. and Y.X. were supported by a CIRM Training Grant (TG2-01169). X.G. was supported by the MSTP program, David Geffen School of Medicine at UCLA. W.E.L. was supported by the Maria Rowena Ross Chair in Cell Biology and Biochemistry, and this work was supported by grants from CIRM (RB3-05207), NIH (P01GM99134-NIGMS), and an Eli & Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA Innovation Award.

This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/3.0/>).

Supplemental Information includes Supplemental Experimental Procedures, four figures, and two tables and can be found with this article online at [http://dx.doi.org/10.1016/j.stemcr.2014.08.015](10.1016/j.stemcr.2014.08.015){#intref0010}.

![*let-7* Activity Correlates with Human Gliogenesis\
(A) Differentiation of human NPCs by growth factor withdrawal drives the generation of neurons and astrocytes. Percentage of positive PSC-NPCs and Tissue-NPCs (7--19 weeks of gestation) undergoing neuronal (TUJ1, MAP2) versus glial (GFAP, S100B, A2B5) differentiation. Error bars represent standard error of the mean (SEM) over three at least three biological replicates.\
(B) Average expression of *LIN28A* and *LIN28B* probe sets from ([@bib31]). PSC-NPCs p1 (n = 7), PSC-NPCs p2 (n = 2), PSC-NPCs p4 (n = 2), 6--8 week tissue-NPCs (n = 6), 15--19 week fetal NPCs (n = 5). Error bars represent SEM over biological replicate lines. Scale bars, 100 μm.\
(C) Percentage of contribution of *let-7* miRNA family members to all miRNA present in cells derived from 16 week Tissue-NPCs (n = 2), 6--7 week Tissue-NPCs (n = 2), and PSC-NPCs (n = 3) by miRNA-seq. Fold change of normalized expression between 16 week Tissue-NPCs and PSC-NPCs for each family member is shown at right. Data for all miRNAs can be found in [Table S1](#mmc2){ref-type="supplementary-material"}.\
(D) Genes differentially expressed between PSC-NPCs (n = 7) and Tissue-NPCs (n = 5) as identified ([@bib31]) and the number of *let-7* targets represented in the data. *let-7* target lists were generated from published articles and TargetScan 5.2.\
(E) Despite having significantly different levels of *let-7*, PSC- and Tissue-NPCs show similar proliferative potential as measured by cell-cycle analysis based on propidium iodide staining and flow cytometry.\
(F) RNA-seq data from the Allen Institute's Brainspan developmental transcriptome database displayed as log-scale reads per kilobase measured (log~2~ RPKM) across the developing human brain. Top, transcription of neuronal, glial and oligodendrocyte marker genes (the average of all markers indicated by boldface line); middle, transcription of *LIN28B*; bottom, transcription of selected *let-7* target genes.\
(G) Top, schematic of *LIN28*'s role in the progression of *let-7* microRNAs and the pathway's temporal correlation with development. Bottom, differentiation propensity of NPCs correlated with gestational age.](gr1){#fig1}

![Dynamics of *let-7* Expression and Processing between PSC-NPCs and Tissue-NPCs\
(A) RT-PCR for mature *let-7* family members normalized against small nucleolar RNA U6 in two PSC-NPCs and two Tissue-NPCs. miR-15a and Sno43 were assayed as controls.\
(B) Real-time RT-PCR for pre and pri *let-7* family members normalized against small nucleolar RNA U6.\
(C) Real-time RT-PCR for pri-*let-7* miRNAs normalized against the relative levels of GAPDH in each cell type.\
(D) miRNA-seq of chromatin-associated primary *let-7* family miRNA transcripts between PSC-NPCs and Tissue-NPCs displayed as reads per kilobase measured (RPKM).\
(E) Real-time RT-PCR for mature *let-7* family miRNAs in PSC-NPCs over three passages normalized against U6. Sno43 was run as a negative control and was unchanged over passage.\
(F) Real-time RT-PCR for primary *let-7* family miRNA transcripts in PSC-NPCs over three passages normalized against U6.\
(G) miRNA-seq of chromatin-associated primary *let-7* family miRNA transcripts in PSC-NPCs over two passages (n = 2 for each group) displayed as reads per kilobase measured (RPKM). Data for miRs-10a, 10b, 15a, and 15b are shown to indicate that *let-7* transcriptional regulation is unique in PSC versus Tissue-NPCs, even over passage, where *let-7a1*, *a2*, *b, c*, and *e* were induced. Error bars in all RT-PCR graphs represent SEM over three to four technical replicates, and results shown are representative of at least three independent experiments.](gr2){#fig2}

![A Role for LIN28/*let-7* in the Developmental Progression of Human Tissue-NPCs\
(A) Averaged robust multiarray average (RMA) normalized expression of selected *let-7* target genes in Tissue-NPCs transfected with *let-7b/g* antagomiRs or nontargeted control antagomiRs by gene expression microarray. Error bars represent SEM across two biological replicates.\
(B) Immunostaining for *HMGA2* in Tissue-NPCs showed that *let-7* antagomirs induce *HMGA2* at the protein level.\
(C) Venn diagram demonstrating the original differences identified by [@bib31] (yellow) and the overlap with gene expression differences (\>1.54-fold change) between *let-7b/g* antagomirs versus nonspecific control (antagCTRL) in Tissue-NPCs (green; n = 2).\
(D) Overlap of published and predicted *let-7* targets with genes changed after transfection of Tissue-NPCs with *let-7b/g* antagomiRs or nontargeted control antagomiRs measured by gene expression microarray.\
(E) Pearson correlations of global gene expression similarity between Tissue-NPCs, Tissue-NPCs transfected with *let-7b/g* antagomiRs or nontargeted control antagomiRs, and PSC-NPCs.\
(F) Immunofluorescence (LEFT) and quantification (RIGHT) for TUJ1 (neurons) and GFAP (glia) on Tissue-NPCs differentiated for 3 weeks in growth factor withdrawal following transfection with *let-7b/g* antagomirs or antag CTRL. p value was calculated with Student's t test for at least 1,200 cells across eight to ten fields of view. Error bars represent SEM over fields of view, and results shown are representative of at least three independent experiments. Scale bar, 100 μm.](gr3){#fig3}

![Direct Introduction of *let-7* miRNAs Affects Developmental Progression of PSC-NPCs\
(A) Averaged RMA normalized expression of selected *let-7* target genes in PSC-NPCs transfected with *let-7b/g* mimics or nontargeted control miRNAs by gene expression microarray. Error bars represent SEM across two biological replicates.\
(B) Venn diagram demonstrating the original differences identified by [@bib31] (yellow), and the overlap with gene expression differences (\>1.54-fold change) between *let-7b/g* mimics versus nonspecific control (miCTRL) in PSC-NPCs (red; n = 2).\
(C) Overlap of published and predicted *let-7* targets with genes changed after transfection of PSC-NPCs with *let-7b/g* mimics or nontargeted control miRNAs measured by gene expression microarray.\
(D) Pearson correlations of global gene expression similarity between PSC-NPCs, PSC-NPCs transfected with *let-7b/g* mimics or nontargeted control miRNAs, and Tissue-NPCs.\
(E) Immunofluorescence (left) and quantification (right) for TUJ1 (neurons) and GFAP (glia) on PSC-NPCs differentiated for 3 weeks in growth factor withdrawal following transfection with *let-7b/g* mimics or miCTRL. p value indicated reflects Student's t test for at least 800 cells in multiple wells and across six fields of view. Error bars represent SEM over fields of view, and results shown are representative of at least three independent experiments. Scale bar, 100 μm.](gr4){#fig4}

![HMGA2 Is a Critical Target of *let-7* in Developmental Progression\
(A) Venn diagram demonstrating the overlap of genes changed in comparisons between neurogenic and gliogenic NPCs in the indicated contexts. Original list (yellow): n = 7 PSC-NPC lines and n = 5 Tissue-NPC lines; mimic experiment (red): n = 2 for both mimic- and control-treated lines; antagomir experiment (green): n = 2 for both antag- and control-treated lines.\
(B) Normalized expression of all probe sets recognizing *HMGA2* in cell types representing developing NPCs. Probe set 208025_s\_at is the only one that recognizes the *HMGA2* isoform containing multiple *let-7* target sites.\
(C) Immunostaining for *HMGA2* in PSC and Tissue-derived NPCs.\
(D) Real-time RT-PCR and western blot for *HMGA2* expression in PSC-NPCs transfected with either control siRNA or each of three different siRNAs against *HMGA2*.\
(E) Percentage of positive PSC-NPCs transfected with either control siRNA or siRNA against HMGA2 undergoing neuronal (MAP2) versus glial (GFAP) differentiation following 3 weeks growth factor withdrawal. Images and quantification are representative of three independent experiments. At least 1,900 cells were analyzed across at least eight fields of view. Error bars represent SEM over fields of view, and these data are representative of at least three independent experiments. Scale bar, 100 μm.](gr5){#fig5}

![*let-7*/HMGA2 Regulates Notch Sensitivity through HES5\
(A) Venn diagram demonstrating overlap of genes changed in comparisons between neurogenic and gliogenic NPCs in the indicated contexts.\
(B) RT-PCR for relative expression after siRNA transfection to suppress *HMGA2* expression.\
(C) PSC-NPCs and Tissue-NPCs show similar levels of nuclear NICD accumulation suggesting that both have similar activation of the NOTCH pathway. Scale bar, 100 μm.\
(D) Using a gamma-secretase inhibitor to block NOTCH activation decreases neuronal differentiation and induces gliogenesis as measured by MAP2 and GFAP staining and quantification. Scale bar, 100 μm.\
(E) Transcription of *HMGA2* and *HES5* quantified by RNA-seq across the developing human brain.\
(F) Gene expression data taken from an in-house database of a variety of human cell types suggests that *HES5* is mostly expressed in the nervous system, whereas all the other family members are scattered throughout various types of cells from different organs (Log2 scale, RMA transformation).\
(G) siRNA silencing of *HES5* shows a 40% knockdown of message compared to scramble control.\
(H) As shown previously in [Figure 5](#fig5){ref-type="fig"}E, inhibition of *let-7* with antagomirs increased neurogenesis at the expense of gliogenesis. Silencing *HES5* blocks this effect demonstrating a clear link between *let-7* and HES5 activity in neurogenesis. ^∗^Student's t test p \< 0.05 for n \> 450 cells in multiple wells. Paired t tests were performed for each manipulation, and only those with significant changes were indicated by ^∗^. Error bars represent SEM over technical replicates. Results shown are representative of at least three independent experiments.\
(I) Chromatin immunoprecipitation with antibody against the active NOTCH1 product, NICD, shows strong enrichment for NICD binding in at two predicted RBPj binding sites in the *HES5* upstream region (2 kp up and 1 kb up, see schematic). This enrichment was lost in cells with siHMGA2. Binding is represented as enrichment of pull-down over input and calculated as a function of enrichment of IgG over input. *RPL30* was employed as a negative control locus for a constitutively expressed gene not sensitive to NOTCH1 signaling. Shown is the average of two experiments.](gr6){#fig6}

![Generation of Oligodendrocytes Is Facilitated by Induction of *let-7*\
(A) At 6 weeks of differentiation toward the oligodendrocyte lineage, OPC markers were identified by immunostaining and quantified in (B).\
(B) Quantification of results presented in (A).\
(C) Following at least 6 weeks of differentiation in either base or glial induction medium, mature oligodendrocytes were identified by immunostaining and quantified in (D). The bottom panels followed a glial induction protocol ([@bib39]) and produced oligodendrocytes after just 6.5 weeks, again, only with *let-7* induction at the NPC stage prior to directed differentiation. At 7.5 weeks, the number of oligodendrocytes produced was considerably larger. Scale bar, 100 mm.\
(D) A quantification of oligodendrocytes in each condition at two time points in each well. Cells were judged as bona fide oligodendrocytes if positive for both O4 and MBP.](gr7){#fig7}

[^1]: Co-first author
